Established in 2003, Atox Bio is a clinical stage biotechnology company that develops novel immunemodulators in areas of major unmet need with a focus on critical care.
AB103, Atox Bio’s lead product, is being developed for severe infections in critically ill patients . AB103 completed a phase 2 study in patients with Necrotizing Soft Tissue Infections (NSTI). Top line results demonstrated that patients treated with AB103 had a meaningful improvement across multiple end points.
AB103 was granted Fast Track and Orphan Drug designations by the FDA.
Pre-clinical research is conducted in the areas of organ injury and inflammatory diseases.
Over $12m were granted for biodefense research by US Army, DARPA and NIAID for the development of therapeutics against a broad family of bacterial toxins, the superantigens.